KDB94001
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
For Research Use Only.
iGlarLixi provides improved early glycaemic control after 12 weeks of treatment compared with basal insulin in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN studies., PMID:40013432
What do the guidelines say about use of biosimilar insulin therapy? Simple practical considerations to guide clinicians in different patient subgroups-Sharing Canadian perspectives., PMID:40013436
Marked improvement in HbA1c following introduction of biosimilar insulin to treatment regimen of children and youth with type 1 diabetes in Mali: A randomised controlled trial., PMID:40033680
An overview of insulin therapy for the non-specialist., PMID:40035222
Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database., PMID:40055991
Safety of iGlarLixi in Japanese People with Type 2 Diabetes: A Post-marketing Database Study., PMID:40056372
Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme., PMID:40083081
Prescription patterns and the cost of antihyperglycemic drugs in patients with diabetes mellitus in Iran from 2014 to 2019., PMID:40096947
Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study., PMID:40098261
Insulin glargine 300 U/mL safety data in pregnancy., PMID:40105254
Hypoglycemia Secondary to Intentional Insulin Poisoning Managed With Intravenous Hydrocortisone., PMID:40110567
A cost-utility analysis of long-acting insulin analogues (detemir, glargine and degludec) for the treatment of adult type 1 diabetes in South Africa., PMID:40122825
Clinical Outcomes of Switching U-100 Intermediate or Basal Insulin to U-200 Insulin Degludec or U-300 Insulin Glargine., PMID:40162894
Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies., PMID:40176458
State Substitution Laws and Uptake of an Interchangeable Insulin Biosimilar., PMID:40184059
The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5., PMID:40186685
Timing of Insulin Glargine 300 U/ML: Does It Really Matter in Terms of Efficacy and Safety at Insulin Initiation?, PMID:40190894
Comparative Study of Efficacy and Safety of Dapagliflozin vs Basal Insulin in Stabilizing Glycemic Variability in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Triple Drug Combination Therapy., PMID:40200608
An open-label, multiple ascending dose trial of orally administered insulin Tregopil in patients with type 1 diabetes mellitus to evaluate its pharmacokinetics, pharmacodynamics, safety and tolerability., PMID:40211481
Clinical Management of Euglycemic Ketoacidosis in a Cat With Congenital Diabetes Mellitus Treated With Insulin and Dapagliflozin., PMID:40254974
Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial., PMID:40267365
Analysis of Patient Education Guides Generated by ChatGPT and Gemini on Common Anti-diabetic Drugs: A Cross-Sectional Study., PMID:40276455
Pharmacokinetics, Pharmacodynamics, and Bioequivalence of Test Insulin Glargine Versus Reference Preparation (Lantus®) in Healthy Male Volunteers-By Euglycemic Clamp Technique., PMID:40284414
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT study., PMID:40288809
Semaglutide treatment for type 2 diabetes in a patient with chronic myeloid leukemia: A case report and review of the literature., PMID:40292250
Clinically meaningful improvements in treatment satisfaction in insulin-naïve people with type 2 diabetes post initiation of insulin glargine 300 U/mL: A post hoc analysis of real-world ATOS study., PMID:40292754
Effectiveness of the dual GIP/GLP1-agonist Tirzepatide in two cases of Alström syndrome, a rare obesity syndrome., PMID:40302276
Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE Study., PMID:40309264
Prescription Dispensing for Insulin Glargine After Interchangeable Biosimilar Designation., PMID:40314944
Insulin/PHMB-grafted sodium alginate hydrogels improve infected wound healing by antibacterial-prompted macrophage inflammatory regulation., PMID:40319298
Investigation of new non-toxic inhibitors of fibril formation and preservatives for insulin preparations its analogues., PMID:40324845
Multicenter, Phase 4 Clinical Study from India to Evaluate the Safety and Efficacy of Insulin Glargine 300 U/ml in Insulin-Naïve People with Type 2 Diabetes Uncontrolled on Oral Anti-hyperglycemic Drugs: SAFEGUARD Study., PMID:40338497
The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4., PMID:40354448
Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database., PMID:40356973
Hypoglycaemia as a cause of dynamic ECG changes: recognition and management., PMID:40379298
Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial., PMID:40388190
Evaluation of an Alternative Approach to Managing Diabetic Ketoacidosis: Combination Rapid-Acting and Basal Subcutaneous Insulin (CRABI-DKA)., PMID:40390456
When to Consider a Diagnosis of Maturity-Onset Diabetes of the Young: Precise Diagnosis Leads to Better Management and Quality of Life for the Patients., PMID:40395699
Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE., PMID:40424051
Post-marketing safety of Lantus and its interchangeable biosimilar Semglee in the United States: A disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) database., PMID:40437951
Healthcare utilization and costs in adults with type 2 diabetes treated with first or second-generation basal insulins in England., PMID:40441739
Insulin-Induced Acanthosis Nigricans., PMID:40458329
Insights on Hospitalisations from the Phase 3a ONWARDS 1-6 Trials of Once-Weekly Insulin Icodec., PMID:40465144
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
Impact of switching from neutral protamine hagedorn insulin (NPH) to glargine insulin on glycemic control and clinical outcomes in pediatric patients with type 1 diabetes., PMID:40491723
Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed-ratio basal insulin glucagon-like peptide-1 receptor agonist combinations?, PMID:40497353
Choice of Insulin Coformulations: Biphasic Insulin Versus Insulin-GlP1RA., PMID:40500836
CGM-Based Real-World Data on the Transition from Glargine U100 to U300 in Children and Adolescents with Type 1 Diabetes., PMID:40506022
In brief: Merilog - a NovoLog biosimilar., PMID:40512611
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
